Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
August 26, 2002
- DIAGNOSTIC NEWS IN BRIEF
August 26, 2002
- WORLD NEWS IN BRIEF
August 26, 2002
- BULLETIN -2-
August 26, 2002
- Korosho to Issue GLP for Medical Devices in September
August 26, 2002
- Taisho, Toyama Aiming at \300 Bil. Ethical Drug Sales in FY2015: Taisho President
August 26, 2002
- Kirin Develops Calves with Human Antibody Genes
August 26, 2002
- Guidant to Acquire Cook Group
August 26, 2002
- Tanabe to Establish JV with aaiPharma
August 19, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 19, 2002
- Gedeon Richter Sues 12 GE Houses for Famotidine Patent Infringement
August 19, 2002
- New Therapeutic GL for Arteriosclerotic Diseases Published
August 19, 2002
- ACNielsen, So-net M3 to Start Market Survey Service via MR-kun
August 19, 2002
- Shionogi to Collaborate with Oncotherapy Science for Genome-based Drug Discovery
August 19, 2002
- Chronic Heart Failure as Additional Indication Approved for Daiichi's Carvedilol
August 19, 2002
- Nippon Kayaku Developing DDS for Anticancer Drugs
August 19, 2002
- Toho Prepared for End Deals if Accord Not to Be Reached on Prices
August 19, 2002
- PRESS SEMINAR
August 19, 2002
- Ca Antagonists to Coexist with AII Antagonists
August 19, 2002
- Terumo's Hepaflush Prefilled Syringes Selling Well
August 19, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…